Showing 4641-4650 of 20465 results for "".
- Short-Term Tolerability of Blood Pressure-Lowering Drugs and Combinationshttps://reachmd.com/news/short-term-tolerability-of-blood-pressure-lowering-drugs-and-combinations/2487280/Key Takeaways Angiotensin II receptor blocker–containing regimens ranked among the best tolerated, with angiotensin II receptor blocker plus calcium channel blocker at the top. Higher discontinuation due to adverse events was observed with calcium chan
- Three-Year Real-World Outcomes With Dupilumab In Severe Asthmahttps://reachmd.com/news/three-year-real-world-outcomes-with-dupilumab-in-severe-asthma/2487282/Key Takeaways At 36 months, 59% of patients continued dupilumab and 41% had discontinued treatment. Among patients who remained on therapy for 36 months, exacerbations and oral corticosteroid use fell while asthma control and lung function improved.
- ACL Reconstruction With LET in Athletes: Randomized Trial Findingshttps://reachmd.com/news/acl-reconstruction-with-let-in-athletes-randomized-trial-findings/2487289/Key Takeaways Adding modified Lemaire LET to ACL reconstruction was associated with better Lysholm, IKDC, and KT1000 side-to-side results at 12 months. Enrollment was limited to athlete patients younger than 40 years with isolated ACL tear, no meniscal
- Solta Medical’s Thermage Receives China Trademark Recognitionhttps://reachmd.com/news/solta-medicals-thermage-receives-china-trademark-recognition/2487286/Solta Medical, Bausch Health Companies Inc.’s aesthetic business, announced that Thermage has received AAA Well-Known Trademark Certification from the China Trademark Association. The certification is reserved for select brands in mainland China and recognizes Thermage’s brand reputation,
- Blood Flow Restriction After ACL Reconstruction Shows No Added Benefithttps://reachmd.com/news/blood-flow-restriction-after-acl-reconstruction-shows-no-added-benefit/2487269/Key Takeaways No statistically significant between-group differences were seen for the primary or secondary outcomes. Both groups improved over time in subjective pain, maximum strength, active and passive range of motion, and IKDC scores. Blo
- Adjunctive Prednisolone Does Not Lower Coronary Lesions in Kawasaki Diseasehttps://reachmd.com/news/adjunctive-prednisolone-does-not-lower-coronary-lesions-in-kawasaki-disease/2487275/Key Takeaways Adjunctive prednisolone was not associated with a lower 1-month incidence of coronary-artery lesions. Prednisolone was associated with lower rescue-therapy use, shorter fever duration, and greater CRP reduction, while coronary z-score dec
- Magnetic Seizure Therapy Matches ECT Remission in Depression Trialhttps://reachmd.com/news/magnetic-seizure-therapy-matches-ect-remission-in-depression-trial/2487274/Key Takeaways Magnetic seizure therapy met the prespecified non-inferiority criterion for remission, although remission was numerically higher with right unilateral ultra-brief pulse-width electroconvulsive therapy. Autobiographical memory worsening wa
- Continuous Superficial Parasternal Blockade After Sternotomyhttps://reachmd.com/news/continuous-superficial-parasternal-blockade-after-sternotomy/2487268/Key Takeaways Continuous blockade was not associated with lower sternal pain on standardized coughing at 24 hours than the single-injection blockade control strategy. No between-group differences were seen in secondary outcomes, including sternal pain
- Familial Melanoma Genes Associated With Expanded Spectrum of Malignancieshttps://reachmd.com/news/familial-melanoma-genes-associated-with-expanded-spectrum-of-malignancies/2487300/A new study published in JAMA Dermatology suggests pathogenic variants (PVs) in familial melanoma susceptibility genes are present in up to 0.9% of the general population. Investigators for the
- Cabotegravir-Rilpivirine Lowers Regimen Failure in LATITUDE Trialhttps://reachmd.com/news/cabotegravir-rilpivirine-lowers-regimen-failure-in-latitude-trial/2487267/Key Takeaways Monthly injections were associated with lower regimen failure than standard oral ART during the randomized phase. Participants first received adherence support, conditional incentives, and oral ART before only those with viral suppression